Track Ardelyx, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Ardelyx, Inc. ARDX · Stock Open Ardelyx, Inc. in new tab

3.09 USD
EPS
-0.23
P/B
4.73
ROE
-34.85
Beta
0.77
Target Price
12.50 USD
Ardelyx, Inc. logo

Ardelyx, Inc.

🧾 Earnings Recap – Q3 2026

Ardelyx shares rose 8.6% after earnings, with investors responding to Q3 revenue growth of 19% year over year and progress on pipeline expansion. IBSRELA’s 23% growth led the quarter, while XPHOZAH grew 7%, a more modest pace.

  • Total Q3 revenue from IBSRELA and XPHOZAH exceeded $125 million, up 19% year over year.
  • IBSRELA revenue was $96.3 million, up 23%; management said total prescriptions and market share continued to grow, while payer friction remains a focus.
  • XPHOZAH revenue was $29.2 million, up 7%; paid prescriptions grew 22% year over year, though management described the dialysis reimbursement environment as complex.
  • Ardelyx fully enrolled its ACCEL Phase III trial of IBSRELA in chronic idiopathic constipation ahead of schedule.
  • The company launched its first IBSRELA direct-to-consumer campaign in September and reported early increases in website traffic; it has not yet established the campaign’s effect on new patient starts.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 18, 2027
EPS-0.23
Book Value0.65
Price to Book4.73
Debt/Equity172.85
% Insiders3.721%
Growth
Revenue Growth0.16%
Estimates
Forward P/E19.56
Forward EPS0.16
Target Mean Price12.50

DCF valuation

Model fair value for Ardelyx, Inc. (ARDX)
Result
Sign in to run the valuation for ARDX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Strong buy · mean target 12.50 USD (low 8.00, high 18.00) · as of 14 Nov 2026
Low 8.00
Mean 12.50
High 18.00
Price 3.09
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Ardelyx, Inc. Logo Ardelyx, Inc. Analysis (ARDX)

United States Health Care Official Website Stock

Is Ardelyx, Inc. a good investment? Ardelyx, Inc. (ARDX) is currently trading at 3.09 USD. Market analysts have a consensus price target of 12.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Ardelyx, Inc. is expected to release its next earnings report on Feb. 18, 2027. The market consensus estimate for Forward EPS is 0.16.

Investor FAQ

Does Ardelyx, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Ardelyx, Inc.?

Ardelyx, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 18, 2027. The company currently has a trailing EPS of -0.23.

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
FRA (Germany) 41X.F
NGM (Sweden) ARDX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 20, 2021 4:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion